This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue


Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.



Supply Update

We're working hard to build capacity to meet the unprecedented demand for SHINGRIX. 

See the Full Update


SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

View reconstitution instructions for SHINGRIX. View additional SHINGRIX videos

Sign up for a Webinar

Tiffany Mond, GSK Medical Science Liaison, presents information about zoster disease, ACIP recommendations, and the clinical profile of SHINGRIX. View additional SHINGRIX videos

A brief review of the key elements from the pivotal clinical trials. View the full length Pivotal Trials video

*Data from the phase 3 ZOE-50 (≥50 years of age) trial and pooled data in individuals ≥70 years of age from the phase 3 ZOE-70 and ZOE-50 trials from subjects randomized to receive 2 doses of SHINGRIX (N=7698 and 8250, respectively) or placebo (N=7713 and 8346, respectively). See study designs on Efficacy page for details.1,2

CDC=Centers for Disease Control and Prevention; ZVL=zoster vaccine live; ACIP=Advisory Committee on Immunization Practices.


  1. Prescribing Information for SHINGRIX.
  2. Lal H, Cunningham AL, Godeaux O, et al, for the ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087-2096.
  3. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108.

All trademarks are the property of their respective owners.